The Stock Of The Week: AbbVie Inc. (ABBV)


As of Wednesday close, AbbVie Inc.’s (NYSE:ABBV) stock was down -$0.4, moving down -0.25 percent to $159.39. The average number of shares traded per day over the past five days has been 5,165,020 shares. 5 times new highs have been achieved over the past 5 days, with a $7.52 gain in that time frame. In the last twenty days, the average volume was 5,925,895, while in the previous 50 days, it was 5,821,108.

Since last month, ABBV stock rose 6.39%. Shares of the company fell to $142.34 on 10/28/22, the lowest level in the past month. A 52-week high of $175.91 was reached on 04/08/22 after having rallying from a 52-week low of $115.10. Since the beginning of this year, ABBV’s stock price has risen by 17.72% or $23.99, and marked a new high 32 times. However, the stock has declined by -9.39% since its 52-week high.

China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal

Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.

Simply click here and the name & trading symbol are yours.


ABBV stock investors should be aware that AbbVie Inc. (ABBV) stock had its last reported insider trading activity 186 days ago on May 23. SEVERINO MICHAEL, the Vice Chairman of the company, disposed of 79,801 shares for $150.90 on May 23. It resulted in a $12,041,780 divestment by the insider. SEVERINO MICHAEL sold 100,000 shares at an average price of $154.04 on May 17. The insider now owns 152,103 shares following the transaction. On May 16, EVP, Chief Strategy Officer Gosebruch Henry O sold 83,960 shares at $155.00 apiece. The transaction was valued at $13,013,800.

Valuation Metrics

Right now, AbbVie Inc. (ABBV) has a P/E ratio of about 21.23. The stock’s beta is 0.66. Besides these, the trailing price-to-sales (P/S) ratio of 4.79, the price-to-book (PB) ratio of 17.65, and the price-to-cash flow ratio of 22.93 may also be considered.

The latest dividend of $1.48 per share was paid out, which is 4.96% more than last year’s $1.41. On Friday October 28 2022, a $0.07 dividend increase was announced.

Financial Health

In the three months ended June 29, AbbVie Inc.’s quick ratio stood at 0.80, while its current ratio was 0.90, showing that the company is not able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending June 29 was 3.78, and the total debt-to-equity ratio was 4.35. On the profitability front, the trailing twelve-month gross margin is 71.20% percent. In the year ended June 29, operating margins totaled 30.60%. Based on annual data, ABBV earned $38.75 billion in gross profit and brought in $56.2 billion in revenue.

A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was 17.90%. Return on equity (ROE) for the past 12 months was 85.60%.

In AbbVie Inc.’s quarter-end financial report for June 29, it reported total debt of $60.4 billion against cash and short-term investments of $47.0 million. According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. ABBV’s revenue rose 3.17% to $14.58 billion during the quarter, while net income inched up to $14.81 billion. While analysts expected AbbVie Inc. to report $3.31 quarterly earnings, the actual figure was $3.37 per share, beating the consensus estimate by 1.80%. During the quarter, the company generated $6.81 billion in EBITDA. The liabilities of AbbVie Inc. were 125.3 billion at the end of its most recent quarter ended June 29, and its total debt was $73.19 billion. The value of shareholders’ equity is $1.77 billion.

Technical Picture

This quick technical analysis looks at AbbVie Inc.’s (ABBV) price momentum. With a historical volatility rate of 12.05%, the RSI 9-day stood at 77.79% on 23 November.

With respect to its five-day moving average, the current AbbVie Inc. price is up by +4.95% percent or $7.52. At present, ABBV shares trade +4.51% above its 20-day simple moving average and +3.55% percent above its 100-day simple moving average. However, the stock is currently trading approximately +14.22% above its SMA50 and +11.07% above its SMA200.

Stochastic coefficient K was 93.68% and Stochastic coefficient D was 89.21%, while ATR was 3.57. Given the Stochastic reading of 91.32% for the 14-day period, the RSI (14) reading has been calculated as 71.37%. As of today, the MACD Oscillator reading stands at 4.29, while the 14-day reading stands at 6.66.

Analyst Ratings

Credit Suisse launched its rating on AbbVie Inc. (NYSE: ABBV) to an Outperform in a note to investors on November 18, 2022. AbbVie Inc. (ABBV) has been rated Overweight by analysts. According to 1 brokerage firm, ABBV is a sell, and 10 firms recommend it is a Hold. There are 1 analyst who say the stock is underweight. A total of 0 analysts rate AbbVie Inc. stock as buy, with 13 recommending it as overweight.

With a median target price of $157.00, the current consensus forecast for the stock is $133.00 – $200.00. Based on these forecasts, analysts predict AbbVie Inc. (ABBV) will achieve an average price target of $159.15.


Please enter your comment!
Please enter your name here